Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCC
The Company is continuing to explore doses in the ongoing dose escalation study and anticipates a final report in Q1 2023.
Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports.
STP705 is a siRNA (small interfering RNA) therapeutic that is composed of two siRNA oligonucleotides, targeting the expression of TGF-β1 and COX-2 mRNA, respectively.
Apart from achieving a 100% CR, the data among the five subjects treated in the cohort also showed improved or stable cosmetic results with an excellent safety profile (no adverse events) and no significant cutaneous skin reactions.
"The latest results from the Phase II clinical study of STP705 for BCC treatment, showing an incredible efficacy without any drug related AEs and SAEs, further validated the broad potential of this drug candidate for treatment of non-melanoma skin cancers and beyond", says Dr. Patrick Lu, PhD, founder, Chairman of the Board, Executive Director, President and CEO of Sirnaomics, in a news release. "Based on the successes of both BCC and isSCC (cutaneous squamous cell carcinoma in situ) clinical studies, Sirnaomics is spearheading the development of the novel polypeptide-based siRNA therapeutics for various types of cancers."
"Achieving a 100% CR is a clear indication that our treatment has the potential to be an alternative to those treatments currently available to patients, which involve surgical excision of lesions," adds Dr. Michael Molyneaux, MD, Executive Director and Chief Medical Officer of Sirnaomics. "To reduce the rate of scarring and achieve a superior cosmetic result compared to surgery could be a potential advantage for patients with BCC and other non-melanoma skin cancers."
The Phase II open label, dose escalation study will also expand the number of participating cohorts to continue to evaluate the safety, tolerability, and efficacy of various doses of STP705 administered as localized injections in patients with BCC.